Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus
Open Access
- 14 November 2013
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-10
Abstract
Introduction. This study aimed to investigate the efficacy of abatacept for arthritis in patients with rhupus, an overlap syndrome between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods. Patients who fulfilled both the 2010 ACR/EULAR criteria for RA classification and the 1997 ACR revised criteria for classification of SLE and received abatacept treatment for arthritis were retrospectively studied. Results. Six rhupus patients who fulfilled the inclusion criteria above were identified. All patients had active arthritis despite receiving antirheumatic drugs including methotrexate when abatacept was initiated. Clinical Disease Activity Index (CDAI) significantly decreased between baseline and 12 weeks () and remained low through 24 weeks. All patients achieved either a good or moderate response according to the EULAR response criteria at 24 weeks. Health Assessment Questionnaire-Disability Index (HAQ-DI) also significantly decreased between baseline and 24 weeks (). In addition, the levels of immunoglobulin G and anti-DNA antibody significantly decreased between baseline and 24 weeks ( and , resp.). Conclusions. Treatment with abatacept is likely to be efficacious in patients with rhupus whose arthritis is refractory to methotrexate. In addition, abatacept may have a moderate effect on abnormal antibody production in rhupus patients.Keywords
This publication has 26 references indexed in Scilit:
- Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patientsRheumatology, 2012
- CD3 ζ defects in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2012
- Mechanisms of B cell autoimmunity in SLEArthritis Research & Therapy, 2011
- Role of Anti-Tumor Necrosis Factor-α Blockers in Inducing Lupus Erythematosus Tumidus in “Rhupus Syndrome”The Journal of Rheumatology, 2011
- Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot studyAnnals of the Rheumatic Diseases, 2011
- Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnnals of the Rheumatic Diseases, 2009
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals of the Rheumatic Diseases, 2008
- Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFαAnnals of the Rheumatic Diseases, 2005
- CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysisHuman Genetics, 2005
- Anti-TNF-?-induced systemic lupus syndromeClinical Rheumatology, 2003